

CUMULATIVE YEAR-END INDEX—2002 SMALL ANIMAL/EXOTICS AUTHOR INDEX

A

- Alleman, A. R., 798
 Anderson, M. A., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A)
 Anderson, W., *Clinical Advances: Update on Feline Diabetes Management*, May supplement (5B)
 Appel, M. J. G., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)
 Applewhite, A. A., 110
 Arther, R.G., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)

B

- Ballam, J., *Clinical Advances: Update on Feline Diabetes Management*, May supplement (5B)
 Barr, S. C., 304, *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)
 Barrs, V. R., 184
 Barten, S. L., *Bayer Exotics Symposium: Selected Papers on the Green Iguana and Antimicrobials in Exotic Pets*, February supplement (2A)
 Beckman, B., 439
 Biery, D. N., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A)
 Binnington, A. G., 41, 53
 Blagburn, B. L., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)
 Bledsoe, D. L., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)
 Boswood, A., 316
 Bowers, L. C., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)
 Breitschwerdt, E. B., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)
 Broce, A. B., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)
 Buonomo, F. C., *Veterinary Therapeutics Highlights*, December supplement (12A)

C

- Cahill-Morasco, R., 712
 Calvert, C. A., 614
 Campbell, K. L., 224
 Carithers, D., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)
 Ciszewski, D., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)
 Cohn, L. A., 277
 Cooper, C., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A)
 Cornell, K. K., 110
 Corrada, Y., 99, 778
 Côté, E., 701

D

- Daniel, G. B., 626
 Davidson, G., 600
 Denholm, I., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)
 DePasquale, M. A., 712
 Dryden, M. W., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A), *Third Annual Flea & Tick Control Symposium*, April supplement (4B)
 Dykes, N. L., 25

E

- Eddlestone, S. M., 452
 El Bahri, L., 884
 Endepols, S., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)
 Evermann, J. E., 390

F

- Flatland, B., 688
 Frank, G., *Clinical Advances: Update on Feline Diabetes Management*, May supplement (5B)
 Fontenot, D. K., 550
 Ford, R. B., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)
 Fordyce, H. H., 526
 Foster, S. E., 184
 Freeman, L. M., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A)

G

- Gannon, K. M., 604
 Garcia-Lacaze, M., 758
 Garner, M. M., *Bayer Exotics Symposium: Selected Papers on the Green Iguana and Antimicrobials in Exotic Pets*, February supplement (2A)
 Gauthier, J. L., *Bayer Zoonosis Symposium*, May supplement (5A)

- Gil, M. C., 400, 556
 Gobello, C., 99, 778
 Gorham, J. R., 390
 Greenacre, C. B., 550
 Greene, C. E., 614
 Gulikers, K. P., 511
 Guptill, L., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)

H

- Hanscom, J. L., *Veterinary Therapeutics Highlights*, December supplement (12A)
 Hansen, O., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)

Harari, J., 908, 918

Harpster, N., 364, 470, 478
Purina Nutrition Forum Proceedings, September supplement (9A)

Head, L. L., 858

Hess, R. S., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A)

Hodgkins, E., *Clinical Advances: Update on Feline Diabetes Management*, May supplement (5B)
 Hoening, M., *Clinical Advances: Update on Feline Diabetes Management*, May supplement (5B)
 Hopkins, T., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)

Hunt, G. B., 184

J

Jacobs, D. E., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)
 Jacobs, M. B., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)
 Jones, P. D., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A)

K

Kaputkin, A. S., 526, 590, 681
 Katayama, M., 868, 874
 Kazakos, G. M., 204
 Kazakos, K. R., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)
 Kealy, R. D., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A)
 Keil, K., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)
 Kelly, M., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A)
 Kirby, R., 758, 922
 Kitchell, B. E., 220
 Kocan, A. A., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)

L

Laflamme, D. P., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A), *Clinical Advances: Update on Feline Diabetes Management*, May supplement (5B)
 Lamb, C. R., 316, 626
 Langer, N., 446
 Langston, C., 540
 Lappin, M. R., *Bayer Zoonosis Symposium*, May supplement (5A)
 Larsen, K. S., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)
 Lawler, D. F., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A)

CUMULATIVE YEAR-END INDEX—2002 SMALL ANIMAL/EXOTICS AUTHOR INDEX

A

- Alleman, A. R., 798
 Anderson, M. A., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A)
 Anderson, W., *Clinical Advances: Update on Feline Diabetes Management*, May supplement (5B)
 Appel, M. J. G., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)
 Applewhite, A. A., 110
 Arther, R.G., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)

B

- Ballam, J., *Clinical Advances: Update on Feline Diabetes Management*, May supplement (5B)
 Barr, S. C., 304, *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)
 Barrs, V. R., 184
 Barten, S. L., *Bayer Exotics Symposium: Selected Papers on the Green Iguana and Antimicrobials in Exotic Pets*, February supplement (2A)
 Beckman, B., 439
 Biery, D. N., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A)
 Binnington, A. G., 41, 53
 Blagburn, B. L., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)
 Bledsoe, D. L., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)
 Boswood, A., 316
 Bowers, L. C., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)
 Breitschwerdt, E. B., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)
 Broce, A. B., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)
 Buonomo, F. C., *Veterinary Therapeutics Highlights*, December supplement (12A)

C

- Cahill-Morasco, R., 712
 Calvert, C. A., 614
 Campbell, K. L., 224
 Carithers, D., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)
 Ciszewski, D., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)
 Cohn, L. A., 277
 Cooper, C., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A)
 Cornell, K. K., 110
 Corrada, Y., 99, 778
 Côté, E., 701

D

- Daniel, G. B., 626
 Davidson, G., 600
 Denholm, I., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)
 DePasquale, M. A., 712
 Dryden, M. W., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A), *Third Annual Flea & Tick Control Symposium*, April supplement (4B)
 Dykes, N. L., 25

E

- Eddlestone, S. M., 452
 El Bahri, L., 884
 Endepols, S., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)
 Evermann, J. E., 390

F

- Flatland, B., 688
 Frank, G., *Clinical Advances: Update on Feline Diabetes Management*, May supplement (5B)
 Fontenot, D. K., 550
 Ford, R. B., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)
 Fordyce, H. H., 526
 Foster, S. E., 184
 Freeman, L. M., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A)

G

- Gannon, K. M., 604
 Garcia-Lacaze, M., 758
 Garner, M. M., *Bayer Exotics Symposium: Selected Papers on the Green Iguana and Antimicrobials in Exotic Pets*, February supplement (2A)
 Gauthier, J. L., *Bayer Zoonosis Symposium*, May supplement (5A)

- Gil, M. C., 400, 556
 Gobello, C., 99, 778
 Gorham, J. R., 390
 Greenacre, C. B., 550
 Greene, C. E., 614
 Gulikers, K. P., 511
 Guptill, L., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)

H

- Hanscom, J. L., *Veterinary Therapeutics Highlights*, December supplement (12A)
 Hansen, O., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)

Harari, J., 908, 918

Harpster, N., 364, 470, 478

Head, E., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A)

Head, L. L., 858

Hess, R. S., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A)

Hodgkins, E., *Clinical Advances: Update on Feline Diabetes Management*, May supplement (5B)

Hoening, M., *Clinical Advances: Update on Feline Diabetes Management*, May supplement (5B)

Hopkins, T., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)

Hunt, G. B., 184

J

- Jacobs, D. E., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)
 Jacobs, M. B., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)
 Jones, P. D., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A)

K

- Kaputkin, A. S., 526, 590, 681
 Katayama, M., 868, 874
 Kazakos, G. M., 204
 Kazakos, K. R., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)
 Kealy, R. D., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A)
 Keil, K., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)
 Kelly, M., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A)
 Kirby, R., 758, 922
 Kitchell, B. E., 220
 Kocan, A. A., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)

L

- Laflamme, D. P., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A), *Clinical Advances: Update on Feline Diabetes Management*, May supplement (5B)
 Lamb, C. R., 316, 626
 Langer, N., 446
 Langston, C., 540
 Lappin, M. R., *Bayer Zoonosis Symposium*, May supplement (5A)
 Larsen, K. S., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)
 Lawler, D. F., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A)

Legendre, L., 439

LePlattenier, H., 234, 292

Clinical Advances: Update on Feline Diabetes Management, May supplement (5B)

Levy, S. A., *Veterinary Therapeutics Highlights*, December supplement (12A)

Li, Y., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A)

Liang, F. T., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)

Lindsay, D. S., 304

Linnell, M., *Clinical Advances: Update on Feline Diabetes Management*, May supplement (5B)

Lucroy, M. D., 128, 140

M

Mader, D. R., *Bayer Exotics Symposium: Selected Papers on the Green Iguana and Antimicrobials in Exotic Pets*, February supplement (2A)

Malik, R., 184

Mathews, K. A., 41, 53

Matousek, J. L., 224

Mayhew, P. D., 526, 590, 681

McAnulty, J. F., 868, 874

McCracken, B., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A)

McDonough, S., *Clinical Advances: Update on Feline Diabetes Management*, May supplement (5B)

McKiernan, A. J., 390

McKiernan, B. C., 934, 944

McLaughlin, R. M., 836

Mealey, K. L., 10

Mehlhorn, H., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)

Meinkoth, J., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)

Melzer, K. J., 953

Mencke, N., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)

Michel, K. E., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A)

Millis, D. L., *Veterinary Therapeutics Highlights*, December supplement (12A)

Montavon, P., 234, 292

Morrow, C. K., 380

Moses, L., 604

Moyers, T., *Veterinary Therapeutics Highlights*, December supplement (12A)

N

National Association of State Public Health Veterinarians, 328, 374

Neer, T. M., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)

Nicastro, A., 701

Nykamp, S. G., 25

O

O'Connor, T. P., *Veterinary Therapeutics Highlights*, December supplement (12A)

Olson, M. E., *Bayer Zoonosis Symposium*, May supplement (5A)

P

Panciera, D. L., 511

Papazoglou, L. G., 204

Payne, P. A., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)

Pazak, H., *Clinical Advances: Update on Feline Diabetes Management*, May supplement (5B)

Pena, F. J., 400, 556

Perkins, M. C., 184

Philipp, M. T., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)

Pool, R. R., 836

Pospischil, R., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)

Preziosi, D. E., 277

Prosek, R., 220

Purcell, J. E., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)

R

Ramiah, S. K., 798

Rand, J. S., *Clinical Advances: Update on Feline Diabetes Management*, May supplement (5B)

Read, M. R., 774

Reiss, A. J., 934, 944

Reuter, K., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)

Richardson, D. J., *Bayer Zoonosis Symposium*, May supplement (5A)

Ritchie, B. W., 550

Rodriguez, D. B., 364, 470, 473

Rosenthal, K. L., *Bayer Exotics Symposium: Selected Papers on the Green Iguana and Antimicrobials in Exotic Pets*, February supplement (2A)

Rudloff, E., 758, 922

Rupprecht, C. E., *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A)

Rust, M. K., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)

S

Sayer, A. A., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A)

Schantz, P. M., *Emerging Vector-Borne and*

Zoonotic Diseases, January supplement (1A)

Schroeder, L., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)

Scrivani, P. V., 25

Selcer, B. A., 110

Sellon, R. K., 953

Settje, T., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)

Shields, P., *Veterinary Therapeutics Highlights*, December supplement (12A)

Smith, G. K., 526, 590, 681, *2001 Purina Nutrition Forum Proceeding*, September supplement (9A)

Smith, S. A., 670, 784

St. John, L. M., 92

Salter, T. W., 962

Swinney, G. R., 184

T

Trostel, C. T., 836

V

Vaughn, M. B., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)

Volmer, P. A., 380

W

Waggoner, M., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)

Wall, M., 614

Watkins, B. A., *2001 Purina Nutrition Forum Proceedings*, September supplement (9A)

Watson, C. L., 128

Weigel, D. L., *Veterinary Therapeutics Highlights*, December supplement (12A)

Weiss, D. J., 670, 784

Wellington, J., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)

Willms, C., 922

Wilson, G. H., 550

Wingfield, W. E., 934, 944

Y

Young, D. R., *Third Annual Flea & Tick Control Symposium*, April supplement (4B)

Z

Zajac, A. M., 304

VOLUME 24 PAGINATION: Small Animal/Exotics

Issue	Pages	Issue	Pages
January	1-60	July	501-561, 580
February	81-148	August	581-637
March	177-241	September	661-722, 747
April	265-335	October	749-811, 822
May	353-408, 428	November	829-887
June	429-482	December	909-963

SMALL ANIMAL/EXOTICS SUBJECT INDEX^a

A

Abortion (see Mating and abortion, in bitches)

Antibiotic therapy, in exotic pets, *Bayer Exotics Symposium: Selected Papers on the Green Iguana and Antimicrobials in Exotic Pets*, February supplement (2A), 5S-12S

B

Bartonella. Emerging Vector-Borne and Zoonotic Diseases, January supplement (1A), 32S-35S

Bone marrow

- collection and assessment of, canine, 670-679
- aspiration biopsy technique, 671-672
- aspiration smears, evaluation of, 674-677
- core biopsy technique, 674
- disorders, classification of, 677
- indications, for bone marrow evaluation, 670-671
- specimens, preparation of, 672-674
- techniques, special, 677
- interpretation of, canine, 784-797
- hematologic disorders, associated with multiple cytopenias, 790-793
- hematologic disorders, associated with neoplastic disorders, 793
- hematologic disorders, associated with neutropenias, 789-790
- hematopoietic disorders, associated with poorly regenerative anemias, 784-789
- primary myelofibrosis, 793

Bone tumors, primary appendicular, in dogs, 128-138, 147

- biopsy, 130
- diagnostic differentials, 129-130
- history and clinical signs, 129
- metastasis, 133-134
- prognostic factors, 134
- radiography, 129
- signalment, 128-129
- staging, 130-131
- treatment, 131-133

Borrelia burgdorferi infection, *Veterinary Therapeutic Highlights*, December supplement (12A), 18S-25S, 27S-31S

C

Canine lameness (see Osteochondrosis)

Cardiac disease, canine, role of survey radiography in diagnosing, 316-326, 352

- assessment, of cardiac shape, 320-321
- assessment, of cardiac size, 317-320
- radiographic signs, of cardiac failure, 321-325

^aPage numbers ending in "S" indicate subjects that appeared in a supplement to *Compendium*.

Cardiopulmonary resuscitation, 922

- advanced cardiac life support update, 924-929
- basic cardiac life support update, 923-924
- guidelines, standard, human, 923

Cefixime, 446-450

Chemotherapy safety, 140-147

- animal wastes, 144
- chemotherapy administration, 141-142
- considerations, general, 140-141
- drug extravasation, 142-143
- fatal reactions, 144
- hypersensitivity reactions, 143-144
- personal protection equipment, 141
- records, 142
- work area, 141

Chlamydophila psittaci, 328-335, 374-378

COX-2 inhibitor (see Deracoxib, effect of)

Cranial vena cava syndrome, 701-710, 741

- clinical presentation, 702-705
- diagnosis, 705-707
- pathogenesis, 701-702
- prognosis, 709
- treatment, 707-709

Cytarzoonosis. Emerging Vector-Borne and Zoonotic Diseases, January supplement (1A), 75-95

D

Deracoxib, effect of, *Veterinary Therapeutics Highlights*, December supplement (12A), 6S-17S

Desmopressin acetate, 962-963, 988

Dexrazoxane, 220-222

Diabetes, feline, *Clinical Advances: Update on Feline Diabetes Management*, May supplement (5B)

- diet aids, in treatment of, 20S
 - drug options, for managing, 7S-9S
 - protein diet, use of, in management of, 10S-16S
 - understanding, 2S-6S
 - urine glucose, monitoring of, S17-S19
- Drug interactions, clinically significant, 10-22
- drug class, specific drug interactions by, 12-19
 - incidence, 10-11
 - mechanisms, 11-12

E

Ehrlichia, 277-289, *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A), 15S-18S

- classification, 277-278
- clinical findings, 279-282
- diagnosis, 282-283

epidemiology, 278

prevention and control, 284

transmission and pathogenesis, 279

treatment, 283-284

zoonotic potential, 284-285

Ehrlichiosis. Emerging Vector-Borne and Zoonotic Diseases, January supplement (1A), 10S-14S

Enteric Clostridial Colonization, in psittacine birds, 550-554

F

Fleas

allergy dermatitis, efficacy in controlling, by Advantage[®], *Bayer Exotics Symposium: Selected Papers on the Green Iguana and Antimicrobials in Exotic Pets*, February supplement (2A), 6S-9S

control, integrated, for the 21st century, *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A), 36S-40S

feeding, disruption of, by imidacloprid, *Third International Flea & Tick Control Symposium*, (4B), 4S-5S

imidacloprid plus permethrin vs. fipronil, evaluation of, 17S-20S

infestation, in exotic pet animals, *Bayer Exotics Symposium: Selected Papers on the Green Iguana and Antimicrobials in Exotic Pets*, February supplement (2A), 10S-13S

susceptibility, of cat fleas, to imidacloprid, *Bayer Exotics Symposium: Selected Papers on the Green Iguana and Antimicrobials in Exotic Pets*, February supplement (2A), 14S-16S

G

Gastrointestinal disease, drug therapies used in, 452-469

antiemetics, 453-456

antimicrobials, 463-464

cytoprotective drugs and antacids, 458-459

emetics, 453

gastric antisecretory drugs, 456-458

immune-modulating drugs, 464-467

motility modifiers, 461-463

protectants, and adsorbents, 459-461

vomiting reflex, 452

Gerontology and longevity, 2001 Purina Nutrition Forum Proceedings, September supplement (9A)

body condition, influence of, on canine osteoarthritis, 8S-12S

cancer prevention, through nutrition, 28S-34S

cardiac disease, nutritional modulation of, 46S-49S

chondroitin sulfate, in prevention and management of osteoarthritis, 24S-27S

cognitive dysfunction, neurological basis for, in aging dogs, 35S-39S

diabetes, feline, nutritional management of, 550–555
early growth and nutrition, influence of, on aging, 48–78
glucosamine, in prevention and management of osteoarthritis, 245–275
immune function, changes in, with advancing age, 405–455
introduction, 1S–3S
osteoarthritis, management of, with nutraceuticals, 556–561
phytochemicals, in bone and joint metabolism, 135–235
Green iguana, *Bayer Exotics Symposium: Selected Papers on the Green Iguana and Antimicrobials in Exotic Pets*, February supplement (2A)
 clinical pathology of, 235–265
 management, and husbandry, 135–225
 metabolic bone diseases in, 275–295
 phosphorous levels in, 435–445
 reproductive surgery in, 305–345
 tail problems in, 35S–375

H

Hazardous drug administration (*see* Chemotherapy safety)
Helicobacter infection, in humans and animals, 688–698
 diagnosis, 689–691
 future, 695
 pathogenesis, 689
 treatment, 691–694
Hemodialysis, in dogs and cats, 540–549
 complications, 546–548
 indications for, 540–543
 intradialytic management, 546
 outcome, 548
 prescription, 545–546
 principles of, 544–545
 procedures, 543–544
Hip dysplasia, canine
 disease and diagnosis, 526–538
 CHD diagnosis, 527–530
 diagnosis and scoring, methods of, 530–535
 genetic control of, 681–687
 heritability, 682–685
 relationship, between phenotype and genotype, 681
 selection pressure, and strategy, for rapid genetic change, 685–686
 treatment, evidence-based, 590–599
 clients, informing about hip surgery, 593–594
 efficacy, determining, 592–593
 indications, for medical (nonsurgical) treatment, 594–596
 orthopedic examination, and differential diagnosis, 594
 prevention, possible treatments, 591
 treatment outcome, 596–597

Hookworms (*see* Zoonotic ascariids)
Hypercalcemia, 380–388
 metabolism, normal, 380–381
 mineral imbalances, diagnostic differentials for, 382–386
 parathyroid hormone interactions, 381
 soft-tissue mineralization, lesions and prevention of, 386–387
 vitamin D interactions, 381–382
Hyperphosphatemia (*see* Hypercalcemia)
Hypertrophic cardiomyopathy, feline, (*see also* Thromboembolism, aortic, associated with feline hypertrophic cardiomyopathy)
 etiology, pathophysiology, and clinical features, 364–373
 clinical features, 366–371
 etiology, 364–365
 pathophysiology, 365–366
 treatment of, 470–476
 angiotensin-converting enzyme inhibitors, 474
 β-blockers, 472
 calcium-channel blockers, 472–474
 diuretic therapy, 470–472
 nitroglycerin, 472
 prognosis, 474–475

I

Iguana (*see also* Green iguana), oral cavity, disease of, *Bayer Exotics Symposium: Selected Papers on the Green Iguana and Antimicrobials in Exotic Pets*, February supplement (2A), 38S–42S
Infective endocarditis, in dogs, 614–625
 bacteremia and adherence, 614–616
 clinical findings, 617–618
 clinical pathology, 618
 diagnosis, 619–621
 diagnostics, special, 618–619
 epizootiology, 616
 pathophysiology, 617
 predisposing factors, 616–617
 prevention, 623
 prognosis, 623
 treatment, 621–623
 valve involvement, 616
Intestinal lymphangiectasia, canine, 953–961
 clinical findings, 954–955
 diagnosis, 955–958
 diagnostic testing, 955
 pathogenesis and etiology, 953–954
 prognosis, 959
 treatment, 958–959
Intussusceptions, diagnosis and treatment of, in dogs, 110–127
 future prospects, 125
 gastroesophageal intussusceptions, 111–116
 intestinal intussusceptions formation, mechanisms of, 111
 intestinal intussusceptions, 118–125
 pylorogastric intussusceptions, 116–118

Lameness, canine (*see* Deracoxib, effect of)
Larva migrans, from pets and wildlife, *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A), 41S–46S
Leishmaniasis

 in American foxhounds, 304–313
 clinical signs, in dogs, 305–306
 diagnosis and antibody responses, 306
 endemic infections, in the United States, 309–310
 future considerations, 310
 life cycle, 304–305
 treatment, 306–309

in North America, *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A), 3S–6S

Leptospirosis, new issues and considerations, *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A), 53S–56S

Longevity (*see* Gerontology and longevity)

Liver, cytologic evaluation of, 798–810

Indications for, 799
sampling techniques, 799–809

Lyme disease

 in dogs, *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A), 19S–23S
 new standards, for diagnosis of, *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A), 24S–27S

M

Malassezia dermatitis, 224–232
associated diseases, 227
classification, 224–225
cutaneous and mucosal colonization, 225
diagnosis, 227–228
predisposing factors, 226–227
treatment, 228–229
virulence factors, 225–226
Midazolam, 774–777
Mating and abortion, in bitches
preattachment period, 400–408
 antiprogestins, 406–407
 biology, and endocrinology, of pregnancy, 401
 early pregnancy detection, 401–402
 estrogens, 404–406
 prostaglandins, 406
 stepwise approach, 400–401
 timing, 402–404
postclassification period, 596–597
 abortion induction, monitoring of, 559
 abortion induction protocols, 557–559
 postclassification period, 599

Myocardial injury

 diagnosis and treatment, 944–952
 incidence and pathophysiology, 934–941

N

Nasopharyngeal disorders, of dogs and cats, 184–200

clinical signs of disease, 185
clinical retrospective study, 190–197
diagnosis, 185–187
discussion, 197–198
nasopharynx, access to, 187–190
Nerve blocks (*see* Oral surgery, regional nerve blocks for, in companion animals)
Nutrition (*see* Gerontology and longevity)

O

Oral surgery, regional nerve blocks for, in companion animals, 439–444
agent and dose, 440
benefits, 439
complications, 442
materials, 440
oral cavity, regional nerve blocks of the, 440–442
Osteochondrosis, 836–854
of the elbow, 845–846
of the hock, 848–850
of the shoulder, 840–845
of the stifle, 846
overview, 837–840

Otitis, canine, *Veterinary Exchange*, March supplement (3A)
otitis media, diagnosis, treatment, and management of, 48–95
otitis media, potential causes of, 108–205

P

Patellar luxation, in dogs and cats
pathogenesis and diagnosis, 234–240
anatomy and biomechanics, 234–235
clinical signs and diagnosis, 237–238
pathogenesis, 235–237
management and prevention, 292–300
prevention, 296–297
prognosis, 296
treatment, 293–296

Penis and prepuce, surgical conditions of the canine, 204–218

Peritoneal dialysis, 758–772

case study, 766
catheter placement, 761–762
catheter selection, 761
clinical use, 768–770
complications, 767–768
dialysate, and additives, 760–761
exchange procedure, 762–763
mechanism of, 758–760
nursing instructions, 763–765
patient factors, 760
stopping, 768

Portosystemic shunting, diagnostic imaging of dogs with suspected, 626–635

diagnostic imaging, role of, 627–633
prognosis, assessment of, 633–634

Pralidoxime, 884–886

Pregnancy loss, noninfectious spontaneous, in bitches, 778–783

bilateral occlusions, of the uterus, 780
clinical approach, 778–779
cystic endometrial hyperplasia, 780
drugs, 780–781
endocrine disorders, nonsexual, 779
genetics, 781
miscellaneous causes, 781–782
nutrition, 781
progesterone deficiency, 779–780

Prostatic diseases, noninfectious, in dogs, 99–108
benign prostatic hyperplasia, 99–102
discussion, 104–105
prostatic cysts, 102
prostatic markers, 104
prostatic neoplasia, 102–104
squamous metaplasia, 102

Pulmonary disease, radiographic signs of, 25–36
clinical applications, 33–34
radiographic signs, using, instead of patterns, 26–32

Pyridostigmine, 92–94

R

Rabies, reemergence, *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A), 575–605

Radiation safety, improving, in the veterinary hospital, 858–867

barrier design, 865–866
equipment maintenance, 866
exposure levels, personal, 859–862
exposure, radiation, factors affecting, 862–864
ionizing radiation, effects of, 858–859
monitoring devices, 864
units of exposure, 864–865

Radiography (*see* Cardiac disease, canine, role of survey radiography in diagnosing; Pulmonary disease, radiographic signs of)

Recombinant vaccine technology, *Recombinant Vaccine Technology*, April supplement (4A), 15–165

Renal disease, progressive, in dogs, *Current Understanding of Progressive Renal Disease in Dogs*, March supplement (3B), 1S–12S

Renal transplantation, in cats

patient selection, and preoperative management, 868–873
preoperative management, of recipient, 872
risk factors, 869–870
selection criteria, for candidates, 868–869
selection criteria, for donor animals, 872
surgery, timing of, 870–872
techniques, complications, and immunosuppression, 874–882
complications, intraoperative and perioperative, 877–878
complications, long-term, 878–879
future prospects, 881

graft rejection, acute, treatment of, 880
immunosuppression, 879–880
surgical techniques, 874–877
survival, projected, 880–881

S

S-Adenosylmethionine, 600–603
Soft-tissue mineralization (*see* Hypercalcemia)
Synovitis (*see* Derocoxib, effect of)

T

Thoracic trauma, blunt, in dogs (*see* Myocardial injury)

Thromboembolism, aortic, associated with feline hypertrophic cardiomyopathy, 478–482
management, 480–481
prevention, 479–480
prognosis, 481

Thyroid function, canine, influence of various medications on, 511–523

amiodarone, 518–519
anticonvulsants, 517–518
cytokines, 519–520
furosemide, 518
glucocorticoids, 516–517
heparin, 520
NSAIDs, 515–516
physiology, thyroid, 512–513
propranolol, 518
radiocontrast agents, 520
stanazolol, 518
sulfonamides, 513–515
thyroxine supplementation, 520
tricyclic antidepressants, 518

U

Uroabdomen, in dogs and cats, 604–612
causes, 604–605
diagnosis, 605–608
pathophysiologic consequences, 605
treatment, 608–611

V

Vaccine technology (*see* Recombinant vaccine technology)

Vector-borne diseases

diagnostic and preventive strategies for, *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A), 615–655
emerging importance of, *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A), 285–315
Web sites on, *Emerging Vector-Borne and Zoonotic Diseases*, January supplement (1A), 668

Virus transmission, interspecies, 390–397
consequences of, 392
crossover into humans, likelihood of, 394
detection of infection, focusing on, 393
examples of, 391
incidence of, 392

mechanisms of persistence, in animal populations, 392-393
vaccination strategies, effects on, 393-394

W

Wound management

using honey, 53-60
antibacterial activity, variations in different honeys, 54-55
dressing technique, 58-59
healing properties, 53-54
history, 53
versus conventional treatment, 56-58

using sugar, 41-50
clinical studies, using sugar therapy, 43
dressing technique, using sugar, 43-49
healing properties, of sugar, 42
sugar paste, use of, 42-43

Z

Zinc toxicosis, in small animals, 712-720
clinical signs, 715
diagnosis, 716
laboratory findings, 715-716
monitoring, 719

pharmacokinetics, 712-714
toxic effects, 714-715
treatment, 716-719

Zoonosis, Bayer Zoonosis Symposium, May supplement (SA)

Giardia, 105-145
helminths, knowledge and attitudes about, 48-95
ownership, pet, by immunocompromised people, 155-255
Zoonotic ascarids, Emerging Vector-Borne and Zoonotic Diseases, January supplement (1A), 547-552

EQUINE AUTHOR INDEX

A

Andrews, F. M., 166
Aubin, M. L., 411

B

Benz, B. G., 734, 817
Blaik, M. A., 734, 817
Bolt, D. M., 724
Boyles, J., *Veterinary Therapeutics Highlights*, December supplement (12A), 335-435
Brashier, M. K., 242
Bratton, C., *Veterinary Therapeutics Highlights*, December supplement (12A), 335-435
Braxmaier, U., 488
Burba, D. J., 724

C

Cashman, C. P., *Veterinary Therapeutics Highlights*, December supplement (12A), 335-435
Cornell, K. K., 891
Costa, L. R. R., 562

D

Dabareiner, R. M., 652
de la Calle, J., 640
Ditikolu, L., *Veterinary Therapeutics Highlights*, December supplement (12A), 335-435
Divers, T. J., 892

E

Eilts, B., 562
Erkert, R. S., 734, 817

F

Foy, J. M., 242

G

Grevemeyer, B., 488

Grooters, A. M., 812

H

Harkins, J. D., *Veterinary Therapeutics Highlights*, December supplement (12A), 335-435
Hubert, J. D., 812
Hughes, C., *Veterinary Therapeutics Highlights*, December supplement (12A), 335-435
Hunter, J. M., 166
Huxtable, C., 892

J

Jansson, N., 888
Jones, S. L., 342
Judd, R. C., 62

K

Karpiesiuk, W., *Veterinary Therapeutics Highlights*, December supplement (12A), 335-435
Koch, C., 562

L

Lakritz, J., 256
Lech, P. J., 484
Lechner, A. E., *Veterinary Therapeutic Highlights*, December supplement (12A), 335-435
Little, D., 342
Lucroy, M. D., 570, 970

M

Mama, K., 411
May, K. A., 150, 570, 970
Mayer, B., *Veterinary Therapeutics Highlights*, December supplement (12A), 335-435
McClure Blackmer, J., 562
Merritt, A. M., 344
Moll, H. D., 150, 570, 970
Mollett, B. A., *Veterinary Therapeutics Highlights*,

December supplement (12A), 335-435
Morgan, P. K., 964

P

Paccamonti, D., 562
Parvianen, A. K., 73
Peek, S., 169
Peroni, J., 490
Porter, B., 892

R

Ramey, D. W., 418
Rashmir-Raven, A. M., 242
Redding, W. R., 342
Rohrbach, B. W., 166
Rumbaugh, M. L., 690

S

Schroedter, D., *Veterinary Therapeutics Highlights*, December supplement (12A), 335-435
Semrad, S., 169
Snook, C. S., 338
Stanar, L. S., 342

T

Tetens, J., 640
Tidus, P. M., 418
Tillotson, K., 964
Tobin, T., *Veterinary Therapeutics Highlights*, December supplement (12A), 335-435
Traub-Dargatz, J. L., 964
Troppmann, A., *Veterinary Therapeutics Highlights*, December supplement (12A), 335-435

V

Van Biervliet, J., 892

W

- White, S. L., 75
- Whitlock, R. H., 166
- Williams, J., 724
- Wilson, W. D., 256
- Woods, W. E., *Veterinary Therapeutics Highlights*, December supplement (12A), 33S-43S

VOLUME 24 PAGINATION: Equine

<i>Issue</i>	<i>Pages</i>	<i>Issue</i>	<i>Pages</i>
January	62-76	July	562-576, 580
February	150-172, 176	August	638-655
March	241-261	September	723-742
April	336-347	October	812-822
May	410-423	November	888-892
June	484-494, 499	December	964-976

EQUINE SUBJECT INDEX^a**A**

- Abdominal trauma, laparoscopic assessment of, 490-494
- Albutrol, detection times for, *Veterinary Therapeutics Highlights*, December supplement (12A), 33S-43S
- Anal atresia, in a foal, 888-890
- Anesthetic techniques, field, 411-417
 - anesthetic agents, 413-414
 - anesthetic maintenance, 414-415
 - preinduction sedation, 411-413
 - recovery, 415
 - support and monitoring, 415
- Anorectoplasty and temporary tube cystotomy in small animals, 891
- Atrial fibrillation
 - evaluation of, 734-740
 - clinical evaluation, 735-738
 - epidemiology, 734-735
 - pathogenesis, 735
 - treatment and prognosis, 817-822

B

- Botulism, 166-172

C

- Castration complications, recognition and management of, 150-162
 - complications, other, 161
 - intraoperative consideration, 152-154
 - postoperative complications, long-term, 158-161
 - preoperative considerations, 150-152
 - short-term postoperative complications, 154-158

D

- Dental prophylaxis, using a pneumatic system, 62-70

^aPage numbers ending in "S" indicate subjects that appeared in a supplement to *Compendium*.

- evaluation and maintenance form, 64
- examination, 63-66
- older horses, 69-70
- pneumatic instruments, 66-67
- routine floating procedure, 67-69
- weanlings and yearlings, 69

D

- Direct ventral hernia, 488-494
- Erythromycin, 256-261
 - adverse reactions, in foals, 258
 - erythromycin formulations, oral, 256-257
 - macrolide antibiotics, nonantimicrobial activities of 258
 - macrolide antibiotics, other, 257
 - oral formulations, 257-258

G

- Genital tumors, external
 - recognizing, 970-976
 - examination/surveillance, 970-971
 - melanoma, 973-974
 - other tumors, 975
 - sarcoid, 974-975
 - squamous cell carcinoma, 971-972
 - squamous papilloma, 972-973
 - surgical treatment of, 570-576

- circumferential posthectomy, 572
- cryotherapy, 572
- drugs, anticancer, perioperative administration of, 574-575
- en bloc resection, 573-574
- laser ablation, 571
- local excision, 571
- phallectomy, 572-573

G

- Glomerulonephritis, 892-902
 - case report, 897-898
 - diagnosis and classification, 896-900

- pathogenesis, 892-896
- treatment and prognosis, 900

I

- Idiopathic eosinophilic enteritis, 342-347

M

- Massage therapy, assessing effectiveness of, 418-423
- Navicular bursa injections, indications for the use of, 652-654
- Neonatal isoerythrolysis, strategies for preventing, 562-569
 - pathogenesis, 562-564
 - strategies, 564-568

P

- Partial parenteral nutrition, in equine neonatal colistrial enterocolitis, 964-969
- Ponazuril, 484-485
- Pythiosis, 812-815
 - diagnosis, 812-813
 - immunotherapy, 813-814
 - medical therapy, 813
 - surgical therapy, 813

R

- Round bale grass hay (*see* Botulism)

S

- Septic phlebitis, in a foal, 73-76
- Shoulder lameness, 640-650
 - osseous lesions, 641-646
 - soft tissue lesions, 646-648
- Skin tumors, common, 242-254
 - melanoma, 251-252
 - sarcoid, 242-248
 - squamous cell carcinoma, 248-251

T

Tarsal bones, large, traumatic injuries of, 724-733
 anatomy, 724-726
 clinical signs and diagnosis, 726-728
 etiology, 726

fractures, of the calcaneus, 729-730
 fractures, of the malleoli, 728-729
 fractures, of the talus, 730-732
Torpey™, Veterinary Therapeutic Highlights, December supplement (12A), 335-435

W

West Nile virus, 338-340
 diagnosis, 339
 prevention and control, 340
 spread, 338-339
 treatment, 339-340

FOOD ANIMAL AUTHOR INDEX

A

Al-Rawashdeh, O. E., S50

C

Callan, R. J., S25
 Capucille, D. J., S66

D

DePeters, E., S82
 Divers, T. J., S18
 Dritz, S. S., S2

E

Elam, T. E., S10

F

Fleck Veenhuizen, M., S10

G

Goodband, R. D., S2
 Gumaar, A. Y., S50

H

House, J. K., S82

K

Kenyon, S. J., S50
 Kinsel, M. L., S34

N

Nelissen, J. L., S2
 Niles, D., S44
 Nour, A. Y. M., S50

P

Panarella, M., S40
 Peek, S. E., S18
 Poore, M. H., S66

R

Rager, K., S82
 Rebhun, B. C., S18
 Risco, C. A., S44, S56, S74, S92
 Rogers, G. M., S66

S

Smith, B. L., S56, S74, S92
 Soenksen, N., S10

T

Thatcher, M.-J., S44
 Tokach, M. D., S2

V

Van Metre, D. C., S25

VOLUME 24 PAGINATION: Food Animal

<i>Issue</i>	<i>Pages</i>
February	S1-S16
March	S17-S32
April	S33-S48
August	S49-S64
September	S66-S80
October	S81-S100

FOOD ANIMAL SUBJECT INDEX

A

Abortion problems, in dairy herds, an epidemiologic approach to investigating, S34-S39
 data, collecting and processing the, S36-S38
 problem, confirming the, S35-S36
 risk group-based sampling, S38
 Artificial insemination and natural service pregnancy rates in dairy herds, seasonal evaluation of, S44-S48
 herds, S45-S46
 pregnancy rates, S46-S48
 statistical analysis, S46

C

Calf nutrition, S82-S91
 calf starters and milk replacers, S88
 cost comparisons, S85-S87
 cost versus growth requirements, S87-S88

cost versus nutritional ingredients, S82-S85
 growth rate and energy partitioning, S88-S89
 water requirements, S88
 Castration, in cattle, S66-S73
 animal welfare issues, S69-S71
 techniques, S66-S69

F

Fenbendazole, S40-S43
 cautions, S42-S43
 dosage and administration, S43
 drug interactions, S43
 indications, S40-S42
 pharmacology, S40
 preparations, S43
 toxicity, acute, S43

H

Herd expansion, dairy, health and production problems associated with, S50-S55
 expansion, and overcrowding, S51-S52
 expansion strategy, S52-S54
 Hypokalemia, in dairy cattle, S18-S24
 acid-base issues, and potassium balance, S19
 clinical signs, S20
 gastrointestinal disease, S20-S21
 insulin, glucose, and potassium balance, S19
 muscle weakness, S21-S22
 nutritional issues, S19-S20
 pathophysiology, S20
 potassium homeostasis, physiology of, S18-S19
 recumbency, S21-S22
 renal disease, S21
 treatment, S22-S23

P

- Porcine proliferative enteropathy, diagnosis and impact, S10-S14
 clinical disease, S11
 diagnosis, S11-S13
 economic impact, S14
 epidemiology and prevalence, S13
 herd performance, impact on, S14
 Postpartum metritis in dairy cattle
 clinical manifestation of, S56-S64
 classification, S59-S60
 diagnosis, S60-S62
 incidence of, S60
 mechanisms, anatomic and protective, S57-S58
 uterine involution, postpartum, S58-S59
 predisposing factors and potential causes of, S74-S80
 risk factors, S75-S77
 uterine pathogens, S77-S79
 therapeutic and management options for, S92-S100
 antimicrobial therapy, S95-S97
 hormonal therapy, S93-S95
 Preputial injuries in bulls, evaluation and medical treatment of, S25-S32
 evaluation, S26-S28
 pathogenesis, S25-S26
 prognosis, S28-S29
 reevaluation, S31
 treatment, S29-S31
 treatment, decision for, S29

W

- Weight variation, managing, to improve feeding plans for nursery pigs, S2
 feed budget, developing the, S6-S7
 feeding strategies, S7-S8
 weaning weight, variation in, S3-S6

Desmopressin (continued from page 963)

is available in 1-ml ampules and 10-ml multiple-dose vials at a concentration of 4 µg/ml.¹ DDAVP tablets (0.1 and 0.2 mg) are also available but are not recommended because they are destroyed in the gastrointestinal tract.¹

STORAGE AND HANDLING

Refrigeration is recommended for both nasal and parenteral DDAVP solutions.¹ However, an unopened bottle of nasal solution is stable for 3 weeks at room temperature.¹ DDAVP should not be frozen. Tablets should be stored at room temperature.

REFERENCES

- Plumb DC: *Veterinary Drug Handbook*, ed 3. Ames, Iowa State University Press, 1999, pp 203-205.

SEPTEMBER 2002 QUIZ ANSWERS**ARTICLE #1**

Collection and Assessment of Canine Bone Marrow—D. J. Weiss,
S. A. Smith

- | | | | | |
|------|------|------|------|-------|
| 1. a | 2. c | 3. e | 4. b | 5. a |
| 6. d | 7. a | 8. e | 9. d | 10. d |

ARTICLE #2

Genetic Control of Canine Hip Dysplasia—A. S. Kapatkin,
P. D. Mayhew, G. K. Smith

- | | | | | |
|------|------|------|------|-------|
| 1. a | 2. d | 3. c | 4. b | 5. a |
| 6. d | 7. b | 8. b | 9. c | 10. a |

ARTICLE #3

Helicobacter: Comparing Effects in Humans and Animals—B. Flatland

- | | | | | |
|------|------|------|------|-------|
| 1. c | 2. d | 3. d | 4. a | 5. b |
| 6. c | 7. c | 8. d | 9. b | 10. d |

ARTICLE #4

Cranial Vena Cava Syndrome—A. Nicastro, E. Côté

- | | | | | |
|------|------|------|------|-------|
| 1. c | 2. b | 3. a | 4. c | 5. b |
| 6. a | 7. a | 8. c | 9. d | 10. b |

ARTICLE #5

Zinc Toxicosis in Small Animals—R. Cabill-Morasco, M. A. DePasquale

- | | | | | |
|------|------|------|------|-------|
| 1. a | 2. d | 3. b | 4. c | 5. d |
| 6. b | 7. d | 8. b | 9. a | 10. c |

ARTICLE #6

Traumatic Injuries of the Large Tarsal Bones in Horses—D. M. Bolt,
J. Williams, D. J. Barba

- | | | | | |
|------|------|------|------|-------|
| 1. c | 2. a | 3. d | 4. b | 5. c |
| 6. d | 7. a | 8. a | 9. d | 10. c |

ARTICLE #7

Atrial Fibrillation in Horses: Pathogenesis and Clinical Evaluation—
B. G. Bentz, R. S. Erkert, M. A. Blaik

- | | | | | |
|------|------|------|------|-------|
| 1. a | 2. e | 3. c | 4. d | 5. e |
| 6. e | 7. b | 8. c | 9. d | 10. e |

ARTICLE #8

Castration in Cattle: A Review of Techniques and Animal Welfare Aspects—D. J. Capucille, M. H. Poore, G. M. Rogers

- | | | | | |
|------|------|------|------|-------|
| 1. e | 2. b | 3. c | 4. d | 5. a |
| 6. b | 7. e | 8. e | 9. e | 10. d |

ARTICLE #9

Predisposing Factors and Potential Causes of Postpartum Metritis in Dairy Cattle—B. I. Smith, C. A. Riso

- | | | | | |
|------|------|------|------|-------|
| 1. c | 2. a | 3. b | 4. d | 5. d |
| 6. d | 7. a | 8. b | 9. d | 10. b |

- Nichols R, Hohenhaus AE: Use of the vasopressin analogue desmopressin for polyuria and bleeding disorders. *JAVMA* 205(2):168-173, 1994.
- Kraus KH: The use of desmopressin in diagnosis and treatment of diabetes insipidus in cats. *Compend Contin Educ Pract Vet* 9(7):752-755, 1987.
- Mansell PD, Parry BW: Changes in factor VIII: Coagulant activity and von Willebrand factor antigen concentration after subcutaneous injection of desmopressin in dogs with mild hemophilia A. *J Vet Intern Med* 5(3):191-194, 1991.
- Johnstone IB, Crane S: The effects of desmopressin on hemostatic parameters in the normal dog. *Can J Vet Res* 50:265-271, 1986.
- Johnstone IB: Desmopressin enhances the binding of plasma von Willebrand factor to collagen in plasmas from normal dogs and dogs with type I von Willebrand's disease. *Can Vet J* 40:645-648, 1999.

